Section Arrow
IMMP.NASDAQ
- Immutep Limited
Quotes are at least 15-min delayed:2025/09/06 00:26 EDT
Regular Hours
Last
 1.65
+0.03 (+1.85%)
Day High 
1.67 
Prev. Close
1.62 
1-M High
1.8663 
Volume 
182.87K 
Bid
1.63
Ask
1.66
Day Low
1.5912 
Open
1.64 
1-M Low
1.59 
Market Cap 
235.81M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.66 
20-SMA 1.7 
50-SMA 1.7 
52-W High 2.72 
52-W Low 1.32 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.33/-0.49
Enterprise Value
237.17M
Balance Sheet
Book Value Per Share
0.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GNPXGenprex0.2295+0.0738+47.40%0.18PE
ADAPAdaptimmune Therapeutics plc0.041-0.01-19.61%-- 
NUVBNuvation Bio3.9+0.48+14.04%-- 
KLTOKlotho Neurosciences Inc0.4851-0.0099-2.00%-- 
IOVAIovance Biotherapeutics2.49+0.29+13.18%-- 
Quotes are at least 15-min delayed:2025/09/06 00:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.